Objectives: To identify non-penicillin-binding protein (PBP) mutations contributing to resistance to the thirdgeneration cephalosporin cefotaxime in Streptococcus pneumoniae at the genome-wide scale.
Introduction
Streptococcus pneumoniae is a leading cause of bacteraemia, meningitis, respiratory tract infections and otitis media worldwide and is responsible for 11% of all deaths in children ,5 years old. 1 Antimicrobial therapy based on b-lactam antibiotics is the recommended treatment regimen against pneumococcal pneumonia, the most active agents being the penicillin amoxicillin and the third-generation cephalosporins cefotaxime and ceftriaxone. 2 Unfortunately, over the past three decades the control of pneumococcal infections has been complicated by the dissemination of antibiotic resistance. In comparison with the marked escalation in penicillin-non-susceptible pneumococci, the rates of resistance to cefotaxime remain low globally. Some regions or countries are nonetheless experiencing noted rises in cefotaxime resistance, which are mainly due to the spread of a few successful resistant clones. 2 A precise understanding of the mechanisms leading to cefotaxime resistance is thus warranted. b-Lactams interact with penicillin-binding proteins (PBPs), a group of membrane-associated enzymes central to the synthesis of the bacterial cell wall and whose inhibition results in growth arrest and lysis. The primary determinant of resistance to b-lactams in S. pneumoniae involves the production of mosaic PBPs with reduced antibiotic-binding affinities, which are acquired by lateral gene transfer events from closely related streptococcal species. 3, 4 Six PBPs have been identified in S. pneumoniae (PBPs 1a, 1b, 2a, 2b, 2x and 3) and alterations in PBPs 2x, 2b and 1a account for virtually all b-lactam resistance. While PBP2b is the primary target of penicillin, cephalosporins mainly interact with PBP2x. 5 -7 Mutations in PBP1a are required for higher levels of resistance to both penicillin and cefotaxime. 8 Other reports have described a role for low-affinity PBP3 in resistance to cefotaxime 9 and for low-affinity PBP2a in resistance to both penicillin and # The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2013; 68: 1718 -1727 doi:10.1093/jac/dkt113 Advance Access publication 21 April 2013 cefotaxime. 9 -14 Nonetheless, the level of resistance conferred by mosaic PBPs cannot always account for the high levels of resistance observed in some resistant isolates and other non-PBP contributors to resistance have been reported. The cell wall of penicillin-non-susceptible isolates is often highly enriched in branched chain muropeptides, a phenomenon that has been linked to mosaic alleles of the murM gene. 15, 16 Furthermore, mutations in a peptidoglycan N-acetylglucosamine (GlcNAc) deacetylase, 17 a peptidoglycan O-acetyltransferase, 18 a putative glycosyltransferase, 19 a serine threonine kinase, 20 a histidine protein kinase part of a two-component signal-transducing system, 21 a phosphate ABC transporter 22 or a putative iron permease 23 have also been shown to alter the level of susceptibility to b-lactams or to be implicated in the development of resistance.
This manifold collection of resistance determinants against b-lactams is rendering sequencing of susceptible and resistant strains an attractive approach to provide a complete view about the cellular events leading to resistance. 23 -28 In this study, we used next-generation sequencing (NGS) with resistance reconstruction by whole-genome transformation to narrow down the list of mutations involved in resistance to the third-generation cephalosporin cefotaxime. We report the identification of known resistance determinants as well as new non-PBP mutations implicated in resistance.
Materials and methods

Bacterial strains, culture conditions and MIC determination
Unless otherwise stated, pneumococci were grown in brain heart infusion broth (Difco) or on blood agar plates as described previously. 29 Cultures were incubated for 16-24 h in a 5% CO 2 atmosphere at 358C. The R6M1, R6M2 and R6M3 cefotaxime-resistant mutants were generated from S. pneumoniae R6 by stepwise increments on Szybalski plates supplemented with concentration gradients of cefotaxime as described previously. 23, 30 For subculturing, colonies were picked in the area of highest antibiotic concentrations and streaked onto blood agar containing either the same concentration of cefotaxime or a gradient of increasing cefotaxime concentrations. The MICs for the resistant cells isolated from the plates with the highest concentrations of antibiotic were determined to confirm the resistance phenotype. Five selection cycles were required to obtain the highly resistant R6M1, R6M2 and R6M3 mutants. Cefotaxime MICs were determined using Etest strips (AB Biodisk) on MuellerHinton agar plates supplemented with 5% sheep blood according to the manufacturer's instructions. The MICs were further confirmed by the microdilution method according to CLSI guidelines.
DNA transformation
To induce competence, bacteria were cultured at 358C in C+Y medium (pH 6.8) 31 until the onset of the exponential phase. The cells were concentrated 10-fold and resuspended in C+Y medium (pH 7.8) supplemented with 15% glycerol, aliquotted and frozen at 2808C. For transformation, competent cells were thawed on ice, diluted 10 times with C+Y medium (pH 7.8) and stimulated with 2 mg/L competence-stimulating peptide 1 for 15 min at 358C in a 5% CO 2 atmosphere. Genomic DNA or PCR product was added to a final concentration of 2 mg/L and the cultures were incubated for 1 h at 308C, followed by 1 h at 358C in a 5% CO 2 atmosphere. The cultures were then plated on tryptone agar containing casamino acids and the appropriate concentration of cefotaxime and incubated for 48 h at 358C in a 5% CO 2 atmosphere. High molecular weight genomic DNA from the R6M1, R6M2 and R6M3 cefotaxime-resistant mutants was extracted with the Wizard Genomic DNA Purification Kit (Promega), according to the manufacturer's instructions, and used to serially transform S. pneumoniae R6 to yield the TM1 and TM2 series of cefotaxime-resistant transformants along with the T1M3 transformant.
For the targeted transformation of PCR products conferring phenotypes less amenable to selection, we employed a co-transformation strategy whereby the PCR products of interest were co-transformed with a PCR product covering the rpsL+ allele (coding for ribosomal protein S12) of S. pneumoniae CP1296. 32 The rpsL+ allele of S. pneumoniae CP1296 codes for a Lys57Thr mutation conferring resistance to streptomycin that enables the selection of transformants under streptomycin pressure. The transformation efficiency of S. pneumoniae R6 is such that as much as 25% of the streptomycin-resistant clones also integrated the PCR product of interest, as confirmed by Sanger sequencing. Only clones having integrated an rpsL+ allele along with the PCR product of interest were conserved.
Whole-genome sequencing
Genomic DNA was prepared from mid-log phase S. pneumoniae cultures using the Wizard Genomic DNA Purification Kit (Promega) according to the manufacturer's instructions. The genomes of R6M1, T3M1 and T3M2 were sequenced using the 454 Life Sciences (Roche) GS-FLX Titanium System. The genome of R6M3 was sequenced with a HiSeq1000 nextgeneration sequencer (Illumina) using a 101 nucleotides paired-end reads protocol. The sequencing, assemblies and comparative analysis for the R6M1, T3M1 and T3M2 strains were performed at the McGill University Genome Quebec Innovation Centre. The sequencing and bioinformatic work for the R6M3 mutant was performed at the Centre de Recherche en Infectiologie of Université Laval. Sequence reads from each strain were aligned to the reference genome S. pneumoniae R6, 33 using the software bwa (bwa aln, version 0.5.9) with default parameters. 34 The maximum number of mismatches was four, the seed length was 32 and two mismatches were allowed within the seed. The detection of single nucleotide polymorphisms was performed using SAMtools (version 0.1.18), bcftools (distributed with SAMtools) and vcfutils.pl (distributed with SAMtools), 35 with a minimum of three reads to call a potential variation prior to further analysis. The sequence data are available at the EMBL European Nucleotide Archive (http://www.ebi.ac.uk/ena) under the study accession number ERP001564; samples ERS153540, ERS153541, ERS153542 and ERS153543 for S. pneumoniae T3M1, R6M1, T3M2 and R6M3, respectively. Mutations deduced from massively parallel sequencing were confirmed by PCR amplification and Sanger sequencing.
Results
Selection and whole-genome sequencing of S. pneumoniae resistant to cefotaxime
The S. pneumoniae R6M1, R6M2 and R6M3 cefotaxime-resistant mutants were selected by exposure of S. pneumoniae R6 wild-type (WT) to stepwise increments of cefotaxime until a final cefotaxime MIC of 4 mg/L (R6M1 and R6M2) or 8 mg/L (R6M3) was reached (Table 1) . It was not possible to obtain mutants resistant to higher levels of cefotaxime. The three cefotaxime-resistant strains were 3 -10-fold cross-resistant to penicillin (Table 1) , but remained susceptible to several other non-b-lactam antibiotics (data not shown).
The reconstruction of antibiotic resistance by the transformation of susceptible bacteria with high molecular weight DNA derived from resistant strains facilitated the discrimination of mutations involved in resistance from bystander mutations Cefotaxime resistance in Streptococcus pneumoniae 1719 JAC selected during the acquisition of resistance. 27 Genomic DNA derived from R6M1, R6M2 and R6M3 was transformed into S. pneumoniae R6 WT recipients and transformants were selected under cefotaxime pressure. Transformants displaying the same level of resistance as the parent mutant were sequenced by NGS. A total of three rounds of transformation were required to fully reconstruct the high-level cefotaxime resistance of the R6M1 and R6M2 mutants, leading to the T3M1 and T3M2 transformants, respectively [ Table 1 and Figure S1 (available as Supplementary data at JAC Online)]. However, we failed to reconstruct the resistance found in R6M3 by wholegenome transformation and never obtained transformants displaying a cefotaxime MIC .0.25 mg/L (Table 1 and Figure S1 ).
We sequenced R6M1, its transformant T3M1 resistant to similar levels of cefotaxime (Table 1) , T3M2 and R6M3 ( Table 2 ). The genome sequence of R6M1 revealed 11 nonsynonymous mutations, of which 6 were transferred to the T3M1 transformant (Table 2 ). These included four missense mutations in pbp2x, a missense mutation in pbp2a and a nonsense mutation in spr1098. The T3M1 strain also acquired spontaneous mutations in spr1120 and spr1870 during its selection under cefotaxime pressure. The genome sequence of T3M2 revealed a total of 11 non-synonymous mutations transferred from R6M2 (Table 2) , including mutations in three PBP genes (pbp2x, pbp2a and pbp3). Of the 11 mutations, 2 (spr0652 and spr0839) occurred spontaneously during the selection of T3M2 since they were absent from R6M2, as determined by targeted sequencing of these genes in the parent mutant.
As transformants were not obtained from R6M3, the genome of this mutant was sequenced. Sequence analysis revealed 17 non-synonymous mutations compared with its WT parent ( Table 2 ). In contrast to R6M1 and R6M2, pbp2x was the only PBP gene mutated in R6M3 (Table 2 ). In fact, pbp2x was the only common mutated gene in every strain sequenced, with the M289T and Q552E substitutions being shared by at least three of the sequenced strains ( Table 2) . The only other genes mutated in more than one strain were the pbp2a gene in T3M1 and T3M2, and the spr0180 and spr1333 genes mutated in T3M2 and R6M3 (Table 2) . Every mutation identified in R6M1, T3M1, T3M2 and R6M3 was confirmed by PCR amplification and conventional DNA sequencing.
PBPs and cefotaxime resistance
The targeted sequencing of the mutations derived from R6M1 at each round of transformation revealed that the Q552E substitution in PBP2x and the A463E change in PBP2a appeared first in the T1M1 transformant selected at 0.5 mg/L cefotaxime (Table 3) . For the transformants of the R6M2 mutant, the only mutation transferred during the first round of transformation selected with 0.125 mg/L was the T550A substitution in PBP2x (Table 4 ). The MIC of cefotaxime for the second-round transformants was either 1.0 mg/L (T2M1) or 2.0 mg/L (T2M2) and the entire set of mutations in PBP2x was transferred (Tables 3 and 4) . The second-level transformant T2M2 also acquired missense mutations in its pbp2a and pbp3 genes ( Table 4) . Transformation of S. pneumoniae R6 WT with pbp genes amplified from the R6M1, R6M2 and R6M3 mutants was conducted to assess the contribution of each PBP mutation to cefotaxime resistance. The pbp2x gene was amplified from genomic DNA derived from the R6M1, R6M2 and R6M3 mutants and the PCR fragments were sequenced to ascertain the presence of the mutations described in Table 2 and transformed into WT cells. The independent selection of transformants with 0.03 mg/L cefotaxime enabled the recovery of the transformants R6
2x-M2 and R6
2x-M3
, all with an increased MIC at 0.5 mg/L (Table 5 ). In a second round of transformation, the pbp2a gene from R6M1 was transformed into the recipient R6 2x-M1
. Selection with 0.5 mg/L cefotaxime yielded second-level transformants that acquired the PBP2a mutation of R6M1 (A463E) and these R6 2x,2a-M1 transformants had an MIC of 1.0 mg/L (Table 5) . Similarly, the transformation of the recipient R6 2x-M2 with a pbp2a PCR fragment amplified from R6M2 yielded the second-level R6 2x,2a-M2 transformant with an MIC of 1.0 mg/L (Table 5) . A third transformation was performed whereby the PBP3 T242K mutation from R6M2 was introduced into R6 2x,2a-M2 recipient cells. The cefotaxime MIC for this transformant, R6 2x,2a,pbp3-M2 , was 2.0 mg/L, only 2-fold less than that for the original parent mutant or transformant (Table 5) .
Non-PBP mutations and cefotaxime resistance
Mutations in PBPs could only partly explain the levels of cefotaxime resistance observed in the T3M1 and T3M2 transformants or in the R6M3 mutant. Other mutations were thus likely to be involved and we first concentrated on recurrent mutations. The spr1333 gene codes for the peptidoglycan GlcNAc deacetylase PgdA with a nonsense mutation in T3M2 and a frameshift mutation in R6M3 (Table 2 ). These mutations were selected late in both strains, i.e. after the mutations in PBPs had appeared when the MIC of cefotaxime was .2.0 mg/L (Tables 4 and 6 ). PCR fragments of pgdA amplified from T3M2 were used as donor DNA for the transformation of R6 2x,2a,pbp3-M2 . The selection of transformants at 2.0 mg/L cefotaxime enabled recovery of the R6 2x,2a,pbp3,spr1333-M2 strain, which had a cefotaxime MIC of 4.0 mg/L (Table 5) , thus allowing a full reconstruction of the cefotaxime resistance of the R6M2 mutant. The only mutation differentiating cells resistant to 1.0 and 2.0 mg/L cefotaxime (1M3 and 2M3) while selecting for R6M3 is the deletion in spr1333 (Table 6 ). Transformation of the spr1333 mutation of R6M3 into 1M3 yielded 1M3
spr1333-M3 with an increased MIC of cefotaxime (Table 5) . Similarly, the introduction of a WT allele of spr1333 into 2M3 reduced resistance to cefotaxime (Table 5) .
Apart from the mutations in pbp2x and pbp2a, the nonsense mutation in the spr1098 gene coding for sortase A (SrtA) was the only other mutation that had been transferred from the R6M1 mutant to its T3M1 transformant, which had the same MIC (Tables 1 and 2 ). We failed to introduce the spr1098 mutation T866C  T866C  T866C  C1565T  M289T  M289T  M289T  P522L  G1264T  G1264T  G1223A  C1654G  G422C  G422C  G408E  Q552E  T1580C  T1580C  A1571G  G1790A  M527T  M527T  Y524C  G597D  C1654G  C1654G  A1648G  G1802T  Q552E  Q552E  T550A  G601V 
Continued
Cefotaxime resistance in Streptococcus pneumoniae into the S. pneumoniae R6 2x,2a-M1 genetic background. However, transformation of the spr1098 mutation from R6M1 into S. pneumoniae R6 WT increased cefotaxime resistance from 0.023 to 0.25 mg/L (Table 5, R6 spr1098-M1 ), while reintroducing a nonmutated version of spr1098 into T3M1 led to a 4-fold sensitization to cefotaxime in the transformants (Table 5) , indicating spr1098 is involved in resistance.
The mutations within the pbp2x and spr1333 genes of R6M3 cannot entirely explain the high level of resistance of this mutant. The genome sequence of R6M3 revealed 12 additional non-synonymous mutations that were acquired during the five distinct cefotaxime increments required for selecting R6M3 and we established the order of appearance of these mutations during the last three increments (1M3 at 1.0 mg/L, 2M3 at 2.0 mg/L and R6M3 at 8.0 mg/L) by targeted sequencing (Table 6 ). The increase in the MIC from 1.0 mg/L in 1M3 to 2.0 mg/L in 2M3 is due to the mutation in spr1333. We then concentrated on the six mutations (spr0180, spr0294, spr0303, Table 3 . Chronological appearance of the identified mutations in R6M1 according to the levels of cefotaxime resistance in whole-genome transformants
R112C
Mutations are shown as nucleotide changes in the first line and as the corresponding amino acid changes in the second line (in bold). a Nonsense mutation.
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spr0981, spr1358 and spr1754) absent from 2M3, but acquired in R6M3 (Table 6 ). The mutations within the glycosyltransferase spr0981 (CpoA) and the LytA autolysin spr1754 were the most attractive due to prior reports about their role in resistance to b-lactams. 19,36 -38 The introduction of the spr0981 mutation from R6M3 into the 2M3 mutant produced the 2M3
spr0981-M3
transformants, which increased the cefotaxime MIC to the level found in R6M3 (8.0 mg/L) ( Table 5) . Similarly, introducing a WT version of spr0981 into R6M3 led to cells being 4-fold more susceptible to cefotaxime (Table 5 ). In contrast, the transformation of the 2M3 mutant with the spr1754 PCR fragment amplified from R6M3 had no impact on the level of resistance of 2M3 to cefotaxime (data not shown).
The early selection steps of R6M3 implicated the acquisition of mutations in the membrane-spanning domain of the spr1255 ABC transporter (phosphate transport) and in the ATP-binding domain of the spr1704 ABC transporter (oligopeptide transport) ( Table 6) . Despite several attempts, we were unsuccessful in obtaining clones when transforming R6 2x-M3 with spr1255 PCR fragments amplified from R6M3. However, transformation of R6 2x-M3 with spr1704 PCR fragments amplified from R6M3 yielded the R6 2x,spr1704-M3 transformant, which had a 2-fold increase in the cefotaxime MIC (Table 5 ). The level of resistance of R6M3 can thus be fully explained by the acquisition of mutations in pbp2x, the mutation in the ABC transporter ATP-binding subunit spr1704, the mutation in the spr1333 peptidoglycan Table 4 . Chronological appearance of the identified mutations in R6M2 according to the levels of cefotaxime resistance in whole-genome transformants
Mutations are shown as nucleotide changes in the first line and as the corresponding amino acid changes in the second line (in bold). a Nonsense mutation. Cefotaxime resistance in Streptococcus pneumoniae JAC GlcNAc deacetylase and, finally, by the mutation in the spr0981 glycosyltransferase.
Discussion
The strategy of reconstructing resistance by whole-genome transformation is a useful approach for narrowing down the list of candidate genes implicated in resistance, because we can select the recombination event directly using antibiotics. We used the combination of resistance reconstruction by transformation and genome sequencing in order to find novel mechanisms of resistance to cefotaxime. Modifications in PBPs are important contributors to resistance to b-lactam antibiotics in clinical isolates of S. pneumoniae and this was also the case in our panel of mutants. In clinical isolates, mosaic genes encoding PBP variants of lower antibiotic-binding affinities are mainly the result of intra-and inter-species gene transfer events involving related streptococcal species. 3, 4 This phenomenon can be mimicked in vitro by the acquisition of point mutations at relevant positions within the transpeptidase domain of PBPs of mutants resistant to b-lactams, as observed here for our S. pneumoniae cefotaximeresistant mutants. PBP2x is one of the primary cefotaxime resistance determinants in S. pneumoniae and the acquisition of a low-affinity PBP2x is a prerequisite for higher levels of resistance. Four pbp2x mutations were selected in each of our mutants (Table 2) , of which the M289T and Q552E substitutions were shown in at least two mutants. The Q552E substitution acquired by both R6M1 and R6M3 mutants is a major determinant of resistance to b-lactam antibiotics. 23,39 -41 Indeed, this mutation is located in the vicinity of the third catalytic motif of the active site of PBP2x 42 and the addition of a negative charge at position 552 of the protein was shown to decrease the b-lactam acylation efficiency of the protein. 39, 43 The M289T substitution acquired by both R6M1 and R6M2 is located away from the catalytic cleft and probably has a more secondary role in resistance, by having only minor effects with respect to the active site of the protein or by having a role only in the background of other mutations. 43 Other PBP2x mutations that have been specifically selected in at least one of our mutants include the T550A substitution located just after the conserved KSG motif and uniquely acquired by the R6M2 mutant, the G422C mutation selected in R6M1 and the G601V and G597D substitutions observed specifically in R6M3. The T550A substitution is an important contributor to low-level cefotaxime resistance in laboratory mutants and clinical isolates of S. pneumoniae 9,44 -48 and was the sole mutation transferred to the T1M2 transformant (cefotaxime MIC 0.125 mg/L) ( Table 4 ). Threonine 550 is located close to the active site of PBP2x, where it is in direct contact with cephalosporins, 39 and the loss of hydrogen bonding between the threonine at position 550 and cefotaxime was shown to account for resistance. 49 The G422C mutation observed in R6M1 is positioned on the surface of the transpeptidase domain, where it is distant from the active site of PBP2x, 43 and its role in resistance is thus probably topological. Likewise, the G601V and G597D mutations acquired by R6M3 face in similar directions in the C-terminal region of helix a11 of PBP2x and probably affect its active site by changing the regional topology of the catalytic cleft due to the introduction of bulkier side chains. 43 Other PBP2x mutations identified in our cefotaxime-resistant strains are expected to have more indirect roles in resistance, such as the G408E, P522L, Y524C and M527T substitutions.
Due to the intrinsically low affinity of PBP2a to b-lactam antibiotics, 50, 51 substitutions in PBP2a were not thought to contribute importantly to resistance. However, an A463E substitution close to the SLN catalytic motif of PBP2a has been selected in both R6M1 and R6M2 mutants and their transformation into S. pneumoniae R6 2x-M1 and R6 2x-M2 conferred additional Table 6 . Chronological appearance of the identified mutations in R6M3 according to the levels of cefotaxime resistance during in vitro selection (Table 5) . This is consistent with other studies reporting the presence of mutation in PBP2a in penicillinresistant and cefotaxime-resistant S. pneumoniae clinical and laboratory isolates. 11, 46, 52 Finally, a T242K mutation located adjacent to the KTG box in the low molecular weight PBP3 was observed in R6M2 and its transformation into R6 2x,2a-M2 increased cefotaxime resistance (Table 5) . Although the precise role of this mutation in resistance remains to be established, it is intriguing that a similar T242I change had previously been detected in S. pneumoniae laboratory mutants resistant to cefotaxime. 9 While mutations in PBPs contributed to cefotaxime resistance in every mutant, non-PBP resistance determinants were highlighted in this study. The gene spr1333, coding for the peptidoglycan GlcNAc deacetylase PgdA, 53 was mutated in both the R6M2 and R6M3 mutants ( Table 2 ). In S. pneumoniae, a significant proportion of the GlcNAc residues within the cell wall are N-deacetylated and the inactivation of pgdA was shown to produce cells expressing fully N-acetylated glycans that are more sensitive to lysozyme, 53 in addition to being less virulent in an intraperitoneal mouse model. 54 While the precise role of PgdA in b-lactam resistance remains to be clarified, it is intriguing that alterations in the level of O-acetylation of peptidoglycan muropeptides influence resistance to penicillin in S. pneumoniae. 18 A pgdA point mutation implicated in resistance to b-lactams has also been described upon transformation of S. pneumoniae R6 with genomic DNA derived from a penicillin-resistant clinical isolate, 17 where a H266Y substitution was shown to confer a 2-fold increase in penicillin resistance. 17 A doubling of resistance for cefotaxime was also experimentally confirmed in our study, which was the result of the pgdA nonsense mutation of R6M2. The H266Y mutation also required a background of altered PBPs to confer b-lactam resistance 17 and this could explain the tardy selection of the inactivating mutations within the pgdA gene of R6M2 (Table 4) and R6M3 (Table 6) .
SrtA is a highly conserved transpeptidase responsible for the covalent attachment of LPXTG motif-containing proteins to the cell wall. 55 In S. pneumoniae, SrtA was shown to be involved in adhesion to pharyngeal cells in vitro 56 and in animal models. 57 While the nonsense mutation within the srtA gene of R6M1 was able to confer resistance to cefotaxime when expressed in an S. pneumoniae WT background, it proved impossible to introduce this mutation into S. pneumoniae R6 2x,2a-M1 . The stop codon at position 121 of SrtA only occurred in the last-level transformant T3M1, however, while other mutations had already been selected. It is possible that a specific genetic background is required for SrtA to confer resistance in the presence of altered PBPs. Consistent with this hypothesis, replacing the mutated spr1098 allele from T3M1 with a functional WT version of the gene caused a 4-fold sensitization to cefotaxime. Interestingly, a decreased expression of sortase-encoding genes as well as several surface protein-encoding genes has been observed in vancomycin-resistant Staphylococcus aureus isolates, 58 suggesting a possibly more global role for sortases in the response to cell wall-induced stresses.
The mutations in srtA and pgdA could, respectively, explain the cefotaxime resistance of R6M1 and R6M2 that was not due to mutations within PBPs, but transformation experiments revealed that an additional mutation in the glycosyltransferase CpoA (spr0981) was required to explain the higher levels of resistance of R6M3 (Table 5) . While the role in resistance for altered alleles of cpoA was thought to be restricted to penicillins, 3, 19 the D213Y mutation in CpoA from R6M3 clearly conferred a 4-fold increase in cefotaxime resistance (Table 5) . Prokaryotic CpoA homologues are involved in teichoic acid or lipopolysaccharide biosynthesis and the S. pneumoniae CpoA was shown to act as a lipid glycosyltransferase by transferring a galactose moiety to monoglucosyldiacylglycerol to produce galactosylglucosyldiacylglycerol, the main glycolipid in S. pneumoniae. 59 It is thus possible that altered cpoA alleles may result in a modified synthesis of the polymer, thereby altering indirectly the property of the cell envelope and modulating the activity of cell wall antibiotics.
The genome sequence of R6M3 revealed that the ABC protein gene spr1704 was also mutated in this mutant. The increase in the cefotaxime MIC following the introduction of the point mutation in spr1704 confirmed the association of this ABC protein gene with resistance to cefotaxime. The genome of S. pneumoniae encodes several ABC proteins, some of which were shown to be involved in drug resistance. 22,25,60 -62 Resistance to b-lactam antibiotics has been extensively studied in S. pneumoniae and while the mosaic pbp genes are well established as primary resistance mechanisms, considerable evidence suggested that other genes may be producing resistance. The whole-genome transformation and sequencing strategy used here proved useful for identifying some of these shared and lineage-specific cefotaxime resistance determinants.
